Igata H, Okabe S
Department of Applied Pharmacology, Kyoto Pharmaceutical University.
Nihon Rinsho. 1992 Jan;50(1):11-7.
Gastric (H+/K+)-ATPase, the proton pump of the parietal cell, is responsible for the final step of acid secretion in the stomach. In 1981, picoprazole, a substituted benzimidazole, was found to inhibit (H+/K+)-ATPase. It was reported in 1983 that omeprazole has the most potent efficacy among the substituted benzimidazoles and today, omeprazole has been used for treatment of gastroduodenal disease. Recently, lansoprazole, similar to omeprazole in chemical structure, was developed in Japan, and several other compounds, such as pantoprazole, E-3810 and NC-1300-O-3, have also been reported to suppress acid secretion through inhibition of (H+/K+)-ATPase. In the present paper the background of the discovery of (H+/K+)-ATPase and development of proton pump inhibitors is reviewed.
胃(H⁺/K⁺)-ATP酶是壁细胞的质子泵,负责胃内酸分泌的最后一步。1981年,发现取代苯并咪唑类药物匹考拉唑可抑制(H⁺/K⁺)-ATP酶。1983年有报道称,奥美拉唑在取代苯并咪唑类药物中疗效最强,如今,奥美拉唑已用于治疗胃十二指肠疾病。最近,在日本研发出了化学结构与奥美拉唑相似的兰索拉唑,并且还报道了其他几种化合物,如泮托拉唑、E-3810和NC-1300-O-3,也可通过抑制(H⁺/K⁺)-ATP酶来抑制酸分泌。本文对(H⁺/K⁺)-ATP酶的发现背景及质子泵抑制剂的研发情况进行了综述。